<DOC>
	<DOCNO>NCT01379144</DOCNO>
	<brief_summary>The primary objective study compare change intraocular pressure ( IOP ) three different dos latanoprost ( 75 , 100 125 ug/ml ) market 50 ug/ml dose , dose range study .</brief_summary>
	<brief_title>A Study Comparing The Efficacy , Safety And Tolerability Of Latanoprost 75 , 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<criteria>Male female , 18 year age old . Primary open angle glaucoma ( POAG ) ocular hypertension ( OHT ) require unilateral bilateral administration intraocular pressure ( IOP ) lower treatment , include patient naïve IOP lowering treatment . IOP ≥ 24 mmHg ≤ 36 mmHg least one eye 8 AM time point baseline/randomization . Closed/barely open anterior chamber angle history acute angle closure . A history discontinue prostaglandin IOP lowering treatment , unless reason discontinuation participation clinical study . Ocular surgery argon laser trabeculoplasty one eye within 3 month prior screen visit . Use anticipate requirement study topical medication know affect IOP . Anticipated need modify systemic medication know affect IOP ( eg , betaadrenergic antagonist , alphaadrenergic agonist , calcium channel blocker , angiotension convert enzyme inhibitor , angiotension II receptor antagonist ) study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>